The OPG/RANKL/receptor activator of nuclear factor κ (RANK) system between osteoblasts and osteoclasts has gained momentum as a new target to alleviate bone-related diseases such as RA and osteoporosis [8]. This evidence concerns the gene TNFRSF11A and rheumatoid arthritis.